Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal update from its Phase 3 CAPTIVATE trial. The company, which specializes in "next-generation" complement inhibitors, announced that its lead candidate, claseprubart (DNTH103), met early responder [...]
As of March 12, 2026, the healthcare landscape has been fundamentally reshaped by the intersection of digital platforms and the "obesity gold rush." At the center of this transformation is Hims & Hers Health (NYSE: HIMS), a company that has navigated a volatile journey from a telehealth disruptor to a central pillar of the modern [...]
Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.
The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant Novo Nordisk (NYSE: NVO). The deal, which effectively ends a high-stakes patent dispute, has propelled HIMS shares to record highs, closing the
As of March 11, 2026, the Dow Jones Industrial Average is grappling with a heavyweight problem. UnitedHealth Group (NYSE: UNH), long the gold standard of the managed care sector and a primary engine of the index’s growth over the last decade, has transformed into its most significant anchor. With
Andel launches a PBM-free employer platform offering Eli Lilly and Company's (NYSE: LLY) Zepbound KwikPen at lower cash prices. CEO Jay Bregman tells Benzinga how the model works and why PBMs can't copy it.
Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages and could face legal risks tied to patents.
On a day marked by deepening global uncertainty and a sharp spike in energy costs, the healthcare sector emerged as the primary beneficiary of a massive "risk-off" migration by institutional investors. As of the market close on March 10, 2026, the Healthcare Select Sector SPDR Fund (NYSEARCA:XLV) gained 1%
The healthcare sector has entered a period of sharp divergence in early 2026, creating a "bifurcated market" where clinical innovation is rewarding a select few while punishing former industry darlings. As of March 10, 2026, the industry is processing a tale of two trajectories: Vertex Pharmaceuticals (NASDAQ: VRTX) has cemented
The long-held dominance of Novo Nordisk (NYSE: NVO) in the global obesity market has been dealt a staggering blow following the release of the "worst-case scenario" results from the REDEFINE 4 Phase 3 trial. For years, the Danish pharmaceutical giant was the undisputed leader of the GLP-1 revolution, but the
As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering "hangover" period in 2023 and 2024, the pharmaceutical giant is currently in the middle of a high-stakes transformation. The company is attempting to [...]
The U.S. Mergers and Acquisitions (M&A) landscape has entered a blistering new phase of activity, shaking off the volatility of the mid-2020s to reach levels of engagement not seen in over half a decade. Driven by a historic flood of "dry powder" and a rapidly stabilizing macroeconomic environment,
